Daewoong Pharmaceutical Signs Technology Introduction Agreement for 15-PGDH Inhibitor INV-008 (Up to KRW 662.5 Billion)
Subsidiary Daewoong Pharmaceutical signs exclusive global technology introduction agreement with InnoBotherapeutics for 15-PGDH inhibitor INV-008
Total contract value up to KRW 662.5 billion for IBD indication (upfront KRW 6.5 billion, development milestones up to KRW 19 billion, regulatory milestones up to KRW 207 billion, sales milestones up to KRW 430 billion) plus separate royalties
Upfront payment of KRW 6.5 billion is non-refundable
Contract term: 15 years from first commercial sale or until latest patent expiry (subject to early termination)
Conditional contract: may be terminated upon clinical or regulatory failure
INV-008 is an IBD therapeutic candidate with mucosal healing mechanism, including expansion to non-IBD indications
KOSPI Filing Information
Filing: Major Management Matters Related to Investment Decision (Major Management Matters of Subsidiary) (INV008 (15PGDH Inhibitor) Technology Introduction Agreement Execution)